Non-alcoholic fatty liver disease (NAFLD) is the most common chronic
liver disease in the world. With the deepening understanding of NAFLD,
more and more evidence has shown that NAFLD is a group of highly
heterogeneous diseases, which is closely related to metabolic
dysfunction. Recent studies have shown that the occurrence of
nonalcoholic fatty liver disease is closely related to the dysbiosis of
intestinal flora. However, due to the abuse of antibiotics, long-term
use of broad-spectrum antibiotics is the most common cause of intestinal
flora disorders. Endocrine and metabolic disorders caused by intestinal
microbiota imbalance promote the occurrence of obesity, and on this
basis induce the emergence of NAFLD. In response to the current
situation of antibiotic resisftance pandemic, phage therapy has emerged
as a potential solution to solve the problem of bacterial resistance.
Relevant clinical studies have shown that fecal bacterial
transplantation (FMT) can improve the clinical symptoms of patients with
chronic liver disease, in which phage participate in the regulating
effect. This suggests that phages may play a role in the treatment of
non-alcoholic fatty liver disease caused by antibiotic resistance, but
there is insufficient clinical evidence to support this therapy.
Therefore, this review will discuss the mechanism of non-alcoholic fatty
liver disease caused by antibiotics resistance and evaluate the
therapeutic effect of bacteriophages.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.